Date(s) - October 31,2021
9:00 am - 2:00 pm
Dr. Martha M. Rumore, Pharm D., JD, MS, LLM, FAPhA
Of Counsel Sorell, Lenna & Schmidt, LLP & Adjunct Professor, Maurice A. Deane School of Law at Hofstra University
Dr. Martha Rumore is a pharmacist/attorney admitted to the NY, NJ, and DC bars. She has a Pharm D. from St. John’s University, a MS in Drug Information from Long Island University, a JD from CUNY School of Law, and an LLM in Intellectual Property from the Benjamin N. Cardozo School of Law. She is currently Of Counsel at the law firm of Sorell, Lenna & Schmidt, LLP in New York and a Clinical Pharmacist at Montefiore Medical Center in New York. At the law firm she focuses on pharmaceutical and medical device intellectual property including all aspects of patent law prosecution and transactional matters. She has over 15 years of law firm experience in the area of pharmaceutical intellectual property, especially generic pharmaceuticals. She has also worked in the pharmaceutical industry and hospital pharmacy, both at the Director level. She taught Pharmacy Law at both Long Island University and Touro College of Pharmacy for close to 20 years. In 2017, she won the Touro Faculty Research and Scholarship Award. Martha is a frequent lecturer and has over 200 publications and presentations. She is a Fellow and former Trustee of the American Pharmacists Association and in 2015 received the APhA-APPM Poster Merit Award. She is also a former member of the American Society for Pharmacy Law Board of Directors and received the 2015 Larry Simonsmeier Legal Writing Award.
ACPE # TBA
1. Examine recent legislative, legal, and regulatory changes impacting pharmacists on the state and federal level.
2. Describe recent court cases that are relevant to pharmacy practice and how those cases may affect the attendee’s behavior in providing pharmacy services.
3. Describe pharmacy federal and state laws, regulations and the role of the state boards of pharmacy.
4. Identify the resources available in addressing and evaluating issues pertaining to controlled substances in both community and institutional pharmacy practice.
5. Describe how medication errors and adverse drug events in prescribing, dispensing, administration and patient education can be prevented.
6. Describe the extent and effect of medication errors on patient health and safety.
7. Evaluate opportunities and challenges for postmarketing surveillance and adverse drug reaction notification and reporting.
8. Identify best practices to decrease potential liability from medication errors.